FDA Approves Reduced Dose of Cabazitaxel for mCRPC

September 18, 2017 – The FDA has approved a cabazitaxel regimen of 20 mg/m2 every 3 weeks in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer who previously received a docetaxel-containing regimen. The agency approved a dose of 25 mg/m2 every 3 weeks in this patient population in 2010. The approval is based on phase III results from the PROSELICA trial published earlier this year. That data showed … (leggi tutto)